In-vitro Investigation of Antibiotics Efficacy Against Uropathogenic Escherichia coli Biofilms and Antibiotic Induced Biofilm Formation at Sub-Minimum Inhibitory Concentration of Ciprofloxacin

References

• Ponnusamy P, Natarajan V, Sevanan M. In vitro biofilm formation by uropathogenic Escherichia coli and their antimicrobial susceptibility pattern. Asian Pac J Trop Med. 2012;5:210–213. doi:10.1016/S1995-7645(12)60026-122305786
   PubMed Web of Science ®Google Scholar
• Ponnusamy P, Nagappan R. Extended spectrum beta-lactamase, biofilm-producing uropathogenic pathogens and their antibiotic susceptibility patterns from urinary tract infection-an overview. Int J Microbiol Res. 2013;4:101–118.
   Google Scholar
• Asadi S, Kargar M, Solhjoo K, Najafi A, Ghorbani-Dalini S. The association of virulence determinants of uropathogenic Escherichia coli with antibiotic resistance. Jundishapur J Microbiol. 2014;7.
   Web of Science ®Google Scholar
• Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113:5–13. doi:10.1016/S0002-9343(02)01054-9
   PubMed Web of Science ®Google Scholar
• Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc Natl Acad Sci. 2000;97:8829–8835. doi:10.1073/pnas.97.16.882910922042
   PubMed Web of Science ®Google Scholar
• Bower JM, Eto DS, Mulvey MA. Covert operations of uropathogenic Escherichia coli within the urinary tract. Traffic. 2005;6:18–31. doi:10.1111/j.1600-0854.2004.00251.x15569242
   PubMed Web of Science ®Google Scholar
• Tabasi M, Karam MRA, Habibi M, Yekaninejad MS, Bouzari S. Phenotypic assays to determine virulence factors of uropathogenic Escherichia coli (UPEC) isolates and their correlation with antibiotic resistance pattern. Osong Public Health Res Perspect. 2015;6:261–268. doi:10.1016/j.phrp.2015.08.00226473094
   PubMedGoogle Scholar
• Tajbakhsh E, Ahmadi P, Abedpour-Dehkordi E, Arbab-Soleimani N, Khamesipour F. Biofilm formation, antimicrobial susceptibility, serogroups and virulence genes of uropathogenic E. coli isolated from clinical samples in Iran. Antimicrob Resist Infect Control. 2016;5:11. doi:10.1186/s13756-016-0109-427042294
   PubMed Web of Science ®Google Scholar
• Shenoy VAARS, Yadav T. The antibiotic susceptibility patterns of uropathogenic Escherichia coli, with special reference to the fluoroquinolones. J Clin Diagn Res. 2013;7:1027.23905095
   PubMedGoogle Scholar
• Mittal S, Sharma M, Chaudhary U. Biofilm and multidrug resistance in uropathogenic Escherichia coli.. Pathog Glob Health. 2015;109:26–29. doi:10.1179/2047773215Y.000000000125605466
   PubMed Web of Science ®Google Scholar
• Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis. 2012;2012.
   Google Scholar
• Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents. 2012;39:45–51. doi:10.1016/j.ijantimicag.2011.09.01322055529
   PubMed Web of Science ®Google Scholar
• Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000–2009). BMC Infect Dis. 2013;13:19. doi:10.1186/1471-2334-13-1923327474
   PubMed Web of Science ®Google Scholar
• Wiedemann B, Heisig A, Heisig P. Uncomplicated urinary tract infections and antibiotic resistance—epidemiological and mechanistic aspects. Antibiotics. 2014;3:341–352. doi:10.3390/antibiotics303034127025749
   PubMedGoogle Scholar
• Florindo C, Costa A, Matos C, et al. Novel organic salts based on fluoroquinolone drugs: synthesis, bioavailability and toxicological profiles. Int J Pharm. 2014;469:179–189. doi:10.1016/j.ijpharm.2014.04.03424746413
   PubMed Web of Science ®Google Scholar
• Schmitz F-J, Jones ME. Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? Int J Antimicrob Agents. 1997;9:1–19. doi:10.1016/S0924-8579(97)00027-718611815
   PubMed Web of Science ®Google Scholar
• Soleimani N, Aganj M, Ali L, Shokoohizadeh L, Sakinc T. Frequency distribution of genes encoding aminoglycoside modifying enzymes in uropathogenic E. coli isolated from Iranian hospital. BMC Res Notes. 2014;7:842. doi:10.1186/1756-0500-7-84225424607
   PubMedGoogle Scholar
• Ali I, Rafaque Z, Ahmed S, Malik S, Dasti JI. Prevalence of multi-drug resistant uropathogenic Escherichia coli in Potohar region of Pakistan. Asian Pac J Trop Biomed. 2016;6:60–66. doi:10.1016/j.apjtb.2015.09.022
   Web of Science ®Google Scholar
• Snyder JA, Haugen BJ, Lockatell CV, et al. Coordinate expression of fimbriae in uropathogenic Escherichia coli.. Infect Immun. 2005;73:7588–7596. doi:10.1128/IAI.73.11.7588-7596.200516239562
   PubMed Web of Science ®Google Scholar
• Hussain A, Ranjan A, Nandanwar N, Babbar A, Jadhav S, Ahmed N. Genotypic and phenotypic profiles of Escherichia coli isolates belonging to clinical sequence type 131 (ST131), clinical non-ST131, and fecal non-ST131 lineages from India. Antimicrob Agents Chemother. 2014;58:7240–7249. doi:10.1128/AAC.03320-1425246402
   PubMed Web of Science ®Google Scholar
• Mittal S, Sharma M, Chaudhary U. Study of virulence factors of uropathogenic Escherichia coli and its antibiotic susceptibility pattern. Indian J Pathol Microbiol. 2014;57:61. doi:10.4103/0377-4929.13089924739833
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 24th Informational Supplement. Document M100–S27. PA: Wayne; 2017.
   Google Scholar
• Solati SM, Tajbakhsh E, Khamesipour F, Gugnani HC. Prevalence of virulence genes of biofilm producing strains of Staphylococcus epidermidis isolated from clinical samples in Iran. AMB Express. 2015;5:47. doi:10.1186/s13568-015-0134-3
   Web of Science ®Google Scholar
• Christensen GD, Simpson W, Younger J, et al. Adherence of coagulase-negative Staphylococci to plastic tissue culture plates: a quantitative model for the adherence of Staphylococci to medical devices. J Clin Microbiol. 1985;22:996–1006. doi:10.1128/JCM.22.6.996-1006.19853905855
   PubMed Web of Science ®Google Scholar
• de Rossi BP, García C, Calenda M, Vay C, Franco M. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections. Int J Antimicrob Agents. 2009;34:260–264. doi:10.1016/j.ijantimicag.2009.02.02219362452
   PubMed Web of Science ®Google Scholar
• Wang A, Wang Q, Kudinha T, Xiao S, Zhuo C. Effects of fluoroquinolones and azithromycin on biofilm formation of Stenotrophomonas maltophilia. Sci Rep. 2016;6:29701.27405358
   PubMed Web of Science ®Google Scholar
• Majtan J, Majtánová Ľ, Xu M, Majtan V. In vitro effect of subinhibitory concentrations of antibiotics on biofilm formation by clinical strains of Salmonella enterica serovar Typhimurium isolated in Slovakia. J Appl Microbiol. 2008;104:1294–1301. doi:10.1111/j.1365-2672.2007.03653.x18028358
   PubMed Web of Science ®Google Scholar
• Mulvey MA, Schilling JD, Hultgren SJ, O’Brien AD. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun. 2001;69(7):4572–4579. doi:10.1128/IAI.69.7.4572-4579.200111402001
   PubMed Web of Science ®Google Scholar
• Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301(5629):105–107. doi:10.1126/science.108455012843396
   PubMed Web of Science ®Google Scholar
• Shimizu T, Harada K. Determination of minimum biofilm eradication concentrations of orbifloxacin for canine bacterial uropathogens over different treatment periods. Microbiol Immunol. 2017;61(1):17–22. doi:10.1111/1348-0421.1246128042660
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis. 2007;44:79–86. doi:10.1086/51007917143821
   PubMed Web of Science ®Google Scholar
• Baharoglu Z, Krin E, Mazel D, Hughes D. RpoS plays a central role in the SOS induction by sub-lethal aminoglycoside concentrations in Vibrio cholerae. PLoS Genet. 2013;9(4):e1003421. doi:10.1371/journal.pgen.100342123613664
   PubMed Web of Science ®Google Scholar
• Goneau LW. Sub-inhibitory antibiotics enhance virulence, persistence, and pathogenesis of uropathogens. MBio. 2007;6:e00356–1.
   Google Scholar
• Adamus-Białek W, Wawszczak M, Arabski M, et al. Ciprofloxacin, amoxicillin, and aminoglycosides stimulate genetic and phenotypic changes in uropathogenic Escherichia coli strains. Virulence. 2019;10(1):260–276. doi:10.1080/21505594.2019.159650730938219
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31:2742–2751. doi:10.1097/01.CCM.0000098031.24329.1014668610
   PubMed Web of Science ®Google Scholar
• Baqai R, Aziz M, Rasool G. Urinary tract infections in diabetic patients and biofilm formation of uropathogens. Infect Dis J Pak. 2008;17:21–24.
   Google Scholar
• Wojnicz D, Tichaczek-Goska D. Effect of sub-minimum inhibitory concentrations of ciprofloxacin, amikacin and colistin on biofilm formation and virulence factors of Escherichia coli planktonic and biofilm forms isolated from human urine. Braz J Microbiol. 2013;44:259–265. doi:10.1590/S1517-8382201300010003724159313
   PubMed Web of Science ®Google Scholar